GlassScriptPhysician profile
Jessika Davis
NPI 1316391410
$4,336.43
in general payments reported to CMS, 2019-2025
23 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $327 · 2021: $984 · 2022: $871 · 2023: $18.45 · 2024: $348 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.07 |
| Education | $136.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.89 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $381.15 | 2021-2025 | |
| Lilly USA, LLC | $348.02 | 2019-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $335.76 | 2020-2025 | Dupixent |
| Janssen Biotech, INC. | $317.00 | 2022-2025 | Tremfya |
| Ucb, INC. | $271.74 | 2020-2025 | Bimzelx |
| Pfizer INC. | $205.39 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $190.31 | 2020-2025 | |
| Genzyme Corporation | $185.25 | 2020-2025 | |
| Amgen INC. | $151.83 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $93.18 | 2020-2022 | |
| Incyte Corporation | $57.64 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $51.48 | 2025 | Anzupgo |
| Epi Health, LLC | $33.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.34 | 2024-2025 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.29 | 2021 | |
| Almirall LLC | $24.29 | 2021 | |
| Biofrontera INC. | $20.53 | 2021 | |
| Vyne Pharmaceuticals INC. | $17.72 | 2020 | |
| Celgene Corporation | $16.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.60 | 2022 | |
| Kyowa Kirin, INC. | $14.28 | 2021 | |
| Oxford Immunotec USA INC | $12.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessika Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.